Brought to you by:
Two-year DETOUR2 study results presented at VAM 2023
Endologix has announced the 24-month results of the DETOUR2 study, presented at VAM 2023, the annual meeting of the Society for Vascular Surgery (SVS), by one of the study’s principal investigators, Sean Lyden, MD, chairman of vascular surgery at the…
BEST-CLI investigators implore a move beyond endo vs. open ‘battle’ in the name of scientific advance
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J. Veith Distinguished Lecture yesterday morning in which they laid bare the blood, sweat and tears shed on their journey to complete the landmark study.…
Sex-related disparities in lower-extremity revascularization outcomes brought into focus
Women are more likely to undergo reintervention after lower extremity revascularization for peripheral arterial disease (PAD) compared to male patients with similar limb salvage and survival outcomes despite having fewer comorbidities, findings of a retrospective analysis presented during the William…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
‘Nobody believed us’: Vascular giant discusses overcoming skeptics to make specialty-defining breakthroughs
Malachi Sheahan III, MD, Vascular Specialist’s medical editor, speaks to living legend and limb-salvage pioneer Frank J. Veith, MD, on the contents of his hard-hitting new book, The Medical Jungle: A Pioneering Surgeon’s Battle to Revolutionize Vascular Care and Challenge…
The top 10 most popular Vascular Specialist stories of May 2023
Last month, Vascular Specialist most piqued reader interest with a commentary from the editor-in-chief on why he supports the decision by the Southern Association for Vascular Surgery (SAVS) to replace its emblem; a guest editorial examining whether physicians nowadays can experience both…
Adding 8–12mm diameter devices to the Shockwave Peripheral Intravascular Lithotripsy toolkit
This advertorial is sponsored by Shockwave Medical. Mazin Foteh, MD, contrasts the benefits of Shockwave Medical’s new Shockwave L6 Peripheral Intravascular Lithotripsy Catheter alongside those of its sister device, the Shockwave M5+ Peripheral Intravascular Lithotripsy Catheter. The Shockwave L6 device…
New ‘biopsychosocial’ roadmap set out to address PAD treatment and mental health impacts
A recent proposal has called for “whole-person, multidisciplinary interventions” after an interrogation of the interplay between lower extremity peripheral arterial disease (PAD) and mental health impacts. Published in the Journal of The American College of Cardiology, researchers have put forward…
Government Grand Rounds: Educating through advocacy
Since the initial launch of the Cancer Moonshot in 2016, the cancer community has made tangible progress towards ambitious goals, including accelerating scientific discovery in cancer, fostering greater collaboration and improving data-sharing. Just last year, U.S. President Joe Biden announced…
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should take back to their multidisciplinary team meetings from the first-time presentation of BASIL-2 led chief investigator…